The 2024 LCRF Research Grants on Understanding Resistance in Lung Cancer from the Lung Cancer Research Foundation (LCRF) supports lung cancer research worldwide that identifies, characterizes, treats, or prevents resistance to therapies in lung tumor cells, tissues, mouse models, and/or patients. The project should address important mechanistic questions and developmental therapeutics across histological subtypes of lung cancer (including lung adenocarcinoma, squamous cell carcinoma and small cell lung cancer) and across the care continuum including newly designed targeted therapies and immunotherapies. The research areas supported by the program include:
- Mechanisms of resistance to targeted therapies for oncogene-driven lung cancers
- Biology and mechanisms of drug resistance to lung cancer therapies; i.e. chemotherapy, immunotherapy and radiotherapy
- Novel treatment approaches and new therapies to overcome and/or prevent resistance to lung cancer therapies
- Novel diagnostic approaches to monitor treatment response and relapse
Applications are open to post-doctoral researchers, clinical fellows, or investigators with less than 10 years of experience since their initial faculty appointment. Applicants may be based at universities and research institutions anywhere in the world. The grant provides 150,000 USD/year over 2 years and does not cover indirect costs.
Letters of intent are due on March 4, 2024, and invited full applications are due on June 10, 2024.
June 10, 2024